(Reuters) – The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer’s sickle cell disease treatment Oxbryta.
Pfizer said late on Wednesday it was pulling the drug from all markets due to risk of a painful complication and death.
The FDA said it was conducting a safety review of postmarketing clinical data for the drug, and will also review real world registry studies.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Krishna Chandra Eluri)
Comments